Articles: function.
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: The ILLUMINATE study evaluated the superiority of once-daily QVA149 110/50μg, a dual bronchodilator combining the LABA indacaterol and LAMA glycopyrronium, compared to twice-daily LABA/ICS, salmeterol/fluticasone 50/500μg (SFC), in terms of efficacy, safety and tolerability in patients with moderate-to-severe COPD. This analysis reports the efficacy and safety of QVA149 versus SFC in the sub-group population using fixed-dose LABA/ICS prior to study enrollment. ⋯ Karen Mezzi: Employee: Novartis Employee John Pallante: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe-to-very severe COPD require intensified therapy to reduce risk of exacerbations. Such patients may benefit from additional bronchodilation. Once-daily QVA149 is a dual bronchodilator consisting of a fixed-dose combination of two long-acting bronchodilators, indacaterol and glycopyrronium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Joachim Ficker: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Ficker has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Nycomed, Almirall, Berlin-C hemie, Takeda and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Angel FowlerTaylor: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Donald Banerji: Employee: The author is an employee of Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Dennis Niewohner, Thomas SandströmClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
This study investigates the change of endothelial cell morphology and function at the rabbit basilar bifurcations in response to sustained high blood flow after bilateral common carotid artery ligation. ⋯ This study is the first to present endothelial cell changes of basilar artery bifurcation in response to sustained high blood flow in rabbits. Endothelial cell impairment possibly initiates aneurysm formation.
-
COPD Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: A giant bulla is defined as an air space in the lung that occupies at least 30% of the hemithorax. Indications for surgical resection are controversial but most commonly include dypnea due to compression of adjacent lung tissue or spontaneous pneumothorax. Previous authors have suggested including mediastinal shift as an indication, but outcome data is lacking. We present a unique case of a 71-year-old patient with bullous emphysema which resulted in compression of the dextrocardial structures. ⋯ The following authors have nothing to disclose: B. Jakub Wilhelm, Aniket Sakharpe, Leopoldo Baccaro, Stanley Ogu, Richard AngelicoNo Product/Research Disclosure Information.
-
Thoracic Surgery PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Poor pulmonary function tests have been shown to be predictors of respiratory complications after lung resection via thoracotomy. Expanding surgical options to lung cancer patients with marginal pulmonary function must be balanced with maintaining patient safety. We sought to determine the role of forced expired volume in one second (FEV1), diffusion capacity to carbon monoxide (DLCO), arterial blood gas (ABG) partial pressures of carbon dioxide and of oxygen (PaCO2, PaO2), smoking status, and smoking history in predicting respiratory complications after robotic-assisted pulmonary lobectomy. ⋯ Eric Toloza: Other: Honoraria for proctoring & observation site The following authors have nothing to disclose: Kathryn Rodriguez, Frank Velez-Cubian, Wei Wei Zhang, Tawee Tanvetyanon, Matthew Thau, Carla Moodie, Joseph Garrett, Jacques-Pierre Fontaine, Lary RobinsonNo Product/Research Disclosure Information.